1. Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
- Author
-
Paloma Gastelurrutia, PhD, Josep Lupón, MD, PhD, Pedro Moliner, MD, Xiaobo Yang, MB, German Cediel, MD, PhD, Marta de Antonio, MD, PhD, Mar Domingo, MD, PhD, Salvador Altimir, MD, Beatriz González, CN, Margarita Rodríguez, CN, Carmen Rivas, CN, Violeta Díaz, CN, Erik Fung, MB, ChB, PhD, Elisabet Zamora, MD, PhD, Javier Santesmases, MD, Julio Núñez, MD, PhD, Jean Woo, MD, and Antoni Bayes-Genis, MD, PhD, FESC
- Subjects
Medicine (General) ,R5-920 - Abstract
Objective: To assess the effects of comorbidities, fragility, and quality of life (QOL) on long-term prognosis in ambulatory patients with heart failure (HF) with midrange left ventricular ejection fraction (HFmrEF), an unexplored area. Patients and Methods: Consecutive patients prospectively evaluated at an HF clinic between August 1, 2001, and December 31, 2015, were retrospectively analyzed on the basis of left ventricular ejection fraction category. We compared patients with HFmrEF (n=185) to those with reduced (HFrEF; n=1058) and preserved (HFpEF; n=162) ejection fraction. Fragility was defined as 1 or more abnormal evaluations on 4 standardized geriatric scales (Barthel Index, Older Americans Resources and Services scale, Pfeiffer Test, and abbreviated-Geriatric Depression Scale). The QOL was assessed with the Minnesota Living with Heart Failure Questionnaire. A comorbidity score (0-7) was constructed. All-cause death, HF-related hospitalization, and the composite end point of both were assessed. Results: Comorbidities and QOL scores were similar in HFmrEF (2.41±1.5 and 30.1±18.3, respectively) and HFrEF (2.30±1.4 and 30.8±18.5, respectively) and were higher in HFpEF (3.02±1.5, P
- Published
- 2018
- Full Text
- View/download PDF